how was semaglutide discovered 30 years of obesity research and over 100 years of medical breakthroughs. Learn more about and the story behind the discovery here: https://lnkd.in/e_as9aKV | Novo Nordisk History of glucagon-like peptide-1 receptor

1000mg Av

That is how medicine is supposed to work and it is how we do it every single time

28.2% in controls) Improved collagen organization and increased deposition Enhanced glutathione levels and antioxidant enzyme activity Increased angiogenesis through VEGF and FGF-2 stimulation Reduced pro-inflammatory markers (TNF-, IL-6) with decreased NF-B signaling Fibroblast migration stimulation and extracellular matrix remodeling GHK-Cu research consistently demonstrates that the peptide is biologically active at very low concentrations in the nanomolar range (110 nM)

The flow through was collected and concentrated to 500 L using a 100 kDa filter (Merck Millipore)

#BMS #Cobenfy #schizophrenia #psychiatry Biotech Executive, Thought Leader & Creator | Diagnostics Executive | Microfluidics & Immunoassay Innovation | FDA Strategy Led EUA 230055, EUA 240006 & 510(k) K240728 | Oncology, AIBiology & IVD Commercialization Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts